MedComm

metrics 2024

Connecting Researchers for Global Impact

Introduction

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor10.70
Journal Impact Factor (5 years)9.70
H-Index-
Journal IF Without Self10.70
Eigen Factor0.00
Normal Eigen Factor0.53
Influence1.99
Immediacy Index1.60
Cited Half Life1.90
Citing Half Life5.10
JCI1.67
Total Documents-
WOS Total Citations1737
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 11/189
Percentile 94.40
Quartile Q1

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 17/189
Percentile 91.01
Quartile Q1

Quartile History

Similar Journals

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Where critical insights meet scientific excellence.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0006-291XFrequency: 52 issues/year

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, published by Academic Press Inc Elsevier Science, stands as a leading periodical in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an ISSN of 0006-291X and an E-ISSN of 1090-2104, this esteemed journal has been a pivotal platform for the dissemination of groundbreaking research since its inception in 1959, continuing to publish influential findings through at least 2024. It holds a commendable Q2 ranking in Biochemistry and Q1 status in Biophysics as of 2023, reflecting its high impact and relevance in the field, supported by its strong Scopus rankings—ranking #43 in Biophysics and maintaining a presence in the top quartiles of several related categories. Although it is not an open-access journal, it provides critical insights and essential data that cater to researchers, professionals, and students keen on advancing their understanding of complex biochemical and biophysical processes. Its significant contributions to the scientific community underscore the importance of this journal as a reference point for innovative research and collaborative discourse.

EXPERIMENTAL AND MOLECULAR MEDICINE

Empowering researchers with open access to cutting-edge findings.
Publisher: SPRINGERNATUREISSN: 1226-3613Frequency: 12 issues/year

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Exploring the depths of disease mechanisms.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

CURRENT MOLECULAR MEDICINE

Unveiling Innovations in Biochemistry and Genetics
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5240Frequency: 10 issues/year

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

International Journal of Molecular and Cellular Medicine

Elevating Understanding in Molecular and Cellular Medicine
Publisher: CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTERISSN: 2251-9637Frequency: 4 issues/year

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Frontiers in Molecular Biosciences

Transforming Research into Understanding in Molecular Sciences
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Molecular Biosciences is an esteemed open-access journal published by FRONTIERS MEDIA SA, based in Switzerland. Since its inception in 2014, the journal has made significant strides in the fields of biochemistry, genetics, and molecular biology, cementing its reputation with a solid position in the Q1 quartile for both Biochemistry and Genetics and Molecular Biology (miscellaneous) categories as of 2023. With a remarkable Scopus rank of #14/103 in the combined categories, it offers an essential platform for the dissemination of high-quality research that shapes the understanding of molecular processes and their implications in health and disease. The journal’s commitment to open access facilitates the broadest possible reach for groundbreaking discoveries, serving as a vital resource for researchers, professionals, and students alike. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, this journal continues to foster innovative discussions and advancements in molecular biosciences, paving the way for new insights and collaborations in the scientific community.

BioImpacts

Advancing the frontiers of biochemistry and medicine.
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5652Frequency: 4 issues/year

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Protein & Cell

Advancing Knowledge in Biochemistry and Cell Biology
Publisher: OXFORD UNIV PRESSISSN: 1674-800XFrequency: 12 issues/year

Protein & Cell, published by Oxford University Press, is a distinguished international journal focusing on cutting-edge research in the fields of biochemistry, biotechnology, cell biology, and drug discovery. This open access journal, active since 2014, is dedicated to disseminating innovative findings that advance our understanding of protein functions and cellular processes, making it an essential resource for researchers, professionals, and students alike. With an impressive 2023 impact factor reflected in its Q1 ranking across multiple categories such as Biochemistry, Drug Discovery, and Cell Biology, 'Protein & Cell' stands at the forefront of scientific research, driving collaboration and discussion in the scientific community. Researchers can access the journal freely online, fostering a global exchange of knowledge and contributing to significant advancements in medicine and biotechnology. Located in the United Kingdom, the journal strives to be a pivotal platform for impactful research that influences future studies and applications.

Molecular Biomedicine

Exploring the Intersection of Biology and Medicine
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

EXPERT OPINION ON THERAPEUTIC TARGETS

Pioneering the future of drug discovery and clinical practice.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.